Using data from the over 100,000 patients currently included in the AACR Project GENIE registry, Pugh and colleagues performed updated comparisons to both The Cancer Genome Atlas and NCI-MATCH and demonstrated important differences that reflect the clinical context of the sequencing represented in GENIE. Importantly, the overall size of GENIE allowed for characterization of drug resistance mechanisms and rare populations, and the comparison with NCI-MATCH demonstrates the ability to use GENIE to provide a data-driven projection of trial enrollment and ultimately can be used to determine when populations are so rare that a trial may not be feasible.

See article, p. 2044.

The α-subunit–specific PI3K inhibitor alpelisib is an active agent in advanced breast cancer, but the clinical utility and biomarkers for patient selection are poorly defined in heavily pretreated disease. Savas, Lo, and colleagues conducted a phase II trial of alpelisib monotherapy in advanced breast cancer showing, in...

You do not currently have access to this content.